Abstract 194P
Background
In cases of persistent inflammation, the migration of immune cells follow the organogenesis of secondary lymphoid organs (SLO) within the organs, leading to the formation of tertiary lymphoid structures (TLS). These structures have become important as diagnostic and prognostic markers in chronic diseases and cancers. However, there is ongoing debate regarding how to assess the maturation of TLS in tissue samples, both in terms of determining the stages themselves and achieving agreement among pathologists. Based on the composition and organization of TLS revealed through imaging mass cytometry (IMC), we aimed to propose a reproducible classification system consisting of three maturation stages for TLS, which can be applied in pathology practice.
Methods
We used formalin-fixed and paraffin-embedded gastric samples (45 tissues with 134 TLS) and colonic samples (50 tissues with 159 TLS), representing inflammatory, cancerous, and control conditions. These samples were subjected to IMC analysis using a panel of 39 markers. Additionally, we sought correlations between markers that reflect the maturation of TLS (composition and architecture). The two IMC-markers with the strongest correlation with TLS maturation were selected to transfer the TLS maturation staging from IMC to dual-staining immunohistochemistry (IHC). This transfer was done to investigate the level of agreement among pathologists when classifying TLS using a set of 60 tissue IHC images.
Results
Using IMC, we were able to characterize the maturation of TLS and propose three distinct stages: Early TLS, Primary Follicle-Like TLS, and Secondary Follicle-Like TLS, identified as IHC CD21-CD23-, CD21+CD23-, and CD21+CD23+, respectively. The analysis of the 60 dual CD21-CD23 IHC images by three pathologists showed a high level of inter-pathologist agreement in classifying TLS into the three maturation stages (Cohen’s Kappa values: > 0.8).
Conclusions
With a strong correlation to cellular and architectural changes during TLS maturation, the dual CD21-CD23 IHC marker allows for the staging of TLS in tissue samples with a high level of inter-pathologist agreement, which holds potential for prognostic and predictive purposes.
Legal entity responsible for the study
M. Le Rochais.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
126P - Evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer
Presenter: Oladapo Yeku
Session: Poster Display
116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer
Presenter: Eric Van Cutsem
Session: Poster Display
127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study
Presenter: Ira Winer
Session: Poster Display
128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab
Presenter: Gerald Falchook
Session: Poster Display
129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Presenter: Brian Kushner
Session: Poster Display
131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_)
Presenter: Anna Di Giacomo
Session: Poster Display
132P - A phase I clinical trial of QLS31905 in advanced solid tumors
Presenter: Yakun Wang
Session: Poster Display
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Presenter: Diwakar Davar
Session: Poster Display
134P - A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors
Presenter: David Pinato
Session: Poster Display
135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial
Presenter: Carlos Becerra
Session: Poster Display